Pfizer, AstraZeneca, and Actelion Separately Report Phase III Trial Failures

Pfizer, AstraZeneca and Actelion last night each reported the failure of one of their drugs in pivotal clinical trials.

Pfizer, AstraZeneca and Actelion last night each reported the failure of one of their drugs in pivotal clinical trials. Pfizer and AstraZeneca separately announced that Phase III trials evaluating their respective drugs, Sutent? and zibotentan, failed to demonstrate the treatments improved overall survival in patients with advanced castration-resistant prostate cancer (CRPC). Actelion said data from the Phase III Conscious-2 study with its Pivlaz? (clazosentan) candidate failed to reach statistical significance in terms of reducing vasospasm-related morbidity and all-cause mortality in clipped patients following aneurismal subarachnoid hemorrhage (aSAH).

Pfizer’s Phase III Sun 1120 Sutent study has been stopped on the advice of the trial’s data monitoring committee, following an interim analysis that showed adding the drug to prednisone therapy was unlikely to impact on overall survival in patients whose CRPC disease had progressed following a docetaxel-based chemotherapy